Alnylam Pharmaceuticals, Inc. (ALNY)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
309.66 USD
-10.47
(-3.271%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 310.05 +0.39 (0.126%) ⇧ (April 17, 2026, 6:55 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:30 p.m. EDT
Momentum is rebuilding higher despite statistical forecasters suppressing short-term upside due to heterogeneous volatility patterns; long-term growth remains solid with projected upside to analyst consensus. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.040273 |
| AutoARIMA | 0.079529 |
| MSTL | 0.080887 |
| AutoETS | 0.082973 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.32 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.727 |
| Excess Kurtosis | 0.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 376.19 |
| Revenue per Share | 28.35 |
| Market Cap | 41,317,285,888 |
| Trailing P/E | 133.47 |
| Forward P/E | 21.94 |
| Beta | 0.38 |
| Profit Margins | 8.45% |
| Website | https://www.alnylam.com |
As of April 18, 2026, 10:30 p.m. EDT: Options flow indicates high speculative positioning on upside, with significant OI and volume spikes at $350 and $450 strikes for near-term expirations. ATM nodes show elevated IV compression, particularly in July 2027, while deep ITM puts (e.g., $150 call covering bets) show inflated IV suggesting insurance hedges rather than directional puts. The expiry live-action around April 17 shows notable open interest concentration at $370, suggesting a floor at this level.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.3304404 |
| Address1 | 675 West Kendall Street |
| Address2 | Henri A. Termeer Square |
| All Time High | 495.55 |
| All Time Low | 3.65 |
| Ask | 310.17 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 1,093,720 |
| Average Daily Volume3 Month | 1,301,941 |
| Average Volume | 1,301,941 |
| Average Volume10Days | 1,093,720 |
| Beta | 0.383 |
| Bid | 308.75 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 5.962 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 309.66 |
| Current Ratio | 2.762 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 326.53 |
| Day Low | 306.04 |
| Debt To Equity | 376.19 |
| Display Name | Alnylam Pharmaceuticals |
| Earnings Call Timestamp End | 1,777,552,200 |
| Earnings Call Timestamp Start | 1,777,552,200 |
| Earnings Timestamp | 1,777,552,200 |
| Earnings Timestamp End | 1,777,552,200 |
| Earnings Timestamp Start | 1,777,552,200 |
| Ebitda | 557,235,968 |
| Ebitda Margins | 0.15004 |
| Enterprise To Ebitda | 73.808 |
| Enterprise To Revenue | 11.074 |
| Enterprise Value | 41,128,394,752 |
| Eps Current Year | 9.24489 |
| Eps Forward | 14.11702 |
| Eps Trailing Twelve Months | 2.32 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 551 8101 |
| Fifty Day Average | 323.366 |
| Fifty Day Average Change | -13.705994 |
| Fifty Day Average Change Percent | -0.04238539 |
| Fifty Two Week Change Percent | 33.04404 |
| Fifty Two Week High | 495.55 |
| Fifty Two Week High Change | -185.88998 |
| Fifty Two Week High Change Percent | -0.37511852 |
| Fifty Two Week Low | 228.28 |
| Fifty Two Week Low Change | 81.380005 |
| Fifty Two Week Low Change Percent | 0.35649204 |
| Fifty Two Week Range | 228.28 - 495.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,086,096,600,000 |
| Float Shares | 132,071,432 |
| Forward Eps | 14.11702 |
| Forward P E | 21.935225 |
| Free Cashflow | 128,788,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,500 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.8164 |
| Gross Profits | 3,032,066,048 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00193 |
| Held Percent Institutions | 1.01096 |
| Implied Shares Outstanding | 133,427,910 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Alnylam Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 41,317,285,888 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_2796659 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 313,747,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 41,317,286,610 |
| Number Of Analyst Opinions | 25 |
| Open | 326.09 |
| Operating Cashflow | 524,080,000 |
| Operating Margins | 0.12007 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.62 |
| Phone | 617 551 8200 |
| Post Market Change | 0.38998413 |
| Post Market Change Percent | 0.12593946 |
| Post Market Price | 310.05 |
| Post Market Time | 1,776,466,543 |
| Previous Close | 320.13 |
| Price Eps Current Year | 33.495262 |
| Price Hint | 2 |
| Price To Book | 51.93895 |
| Price To Sales Trailing12 Months | 11.124929 |
| Profit Margins | 0.08448 |
| Quick Ratio | 2.514 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.78571 |
| Region | US |
| Regular Market Change | -10.47 |
| Regular Market Change Percent | -3.27055 |
| Regular Market Day High | 326.53 |
| Regular Market Day Low | 306.04 |
| Regular Market Day Range | 306.04 - 326.53 |
| Regular Market Open | 326.09 |
| Regular Market Previous Close | 320.13 |
| Regular Market Price | 309.66 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,495,056 |
| Return On Assets | 0.0681 |
| Return On Equity | 0.73283 |
| Revenue Growth | 0.849 |
| Revenue Per Share | 28.35 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 133,427,910 |
| Shares Percent Shares Out | 0.0379 |
| Shares Short | 5,056,408 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,572,652 |
| Short Name | Alnylam Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0505 |
| Short Ratio | 4.49 |
| Source Interval | 15 |
| State | MA |
| Symbol | ALNY |
| Target High Price | 566.0 |
| Target Low Price | 310.0 |
| Target Mean Price | 449.12 |
| Target Median Price | 450.0 |
| Total Cash | 2,908,484,096 |
| Total Cash Per Share | 21.93 |
| Total Debt | 2,968,797,952 |
| Total Revenue | 3,713,936,896 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.32 |
| Trailing P E | 133.47414 |
| Trailing Peg Ratio | 0.6212 |
| Triggerable | 1 |
| Two Hundred Day Average | 393.6213 |
| Two Hundred Day Average Change | -83.9613 |
| Two Hundred Day Average Change Percent | -0.21330477 |
| Type Disp | Equity |
| Volume | 1,495,056 |
| Website | https://www.alnylam.com |
| Zip | 2,142 |